0511 GMT - Raffles Medical Group's profitability is likely to improve, DBS Group Research analysts say in a research report. Gestational losses at its Shanghai and Chongqing hospitals in China should narrow, with the healthcare service provider executing plans to achieve Ebitda breakeven by 2026, the analysts say. Top-line growth in its insurance business should drive operating leverage and boost margins, barring significant deviations in the claims ratio, the analysts say. Raffles Medical has also revised its dividend policy to pay out at least 50% of sustainable earnings annually, the analysts add. DBS upgrades Raffles Medical to buy from hold and raises the stock's target price to S$1.12 from S$0.97. Shares are 1.1% higher at S$0.915. (ronnie.harui@wsj.com)
(END) Dow Jones Newswires
February 26, 2025 00:12 ET (05:12 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.